Ab&B Bio-Tech Co., Ltd. JSHKEX: 2627

(I) resignation of executive director and chief financial officer (ii) nomination of executive directors (iii) appointment of chief financial officer (iv) change of members of board committees (v) appointment of board secretary and joint company secretary (vi) waiver from strict compliance with rules 3.28 and 8.17 of the listing rules (vii) change of authorized representative and (viii) continued suspension of trading

· Issued by Ab&B Bio-Tech Co., Ltd. JS via HKEXnews

Filed with HKEX · Stock code 2627 · · 6 pages · English

On 6ix: 6ix.com/news/i-resignation-of-executive-director-and-chief-financial-officer-ii-nomination-of-executive-directors-iii-appointment-of-chief-financial-officer-iv-change-of-members-of-board-committees-v-appointment-of-board-secretary-and-joint-company-secretary-vi-waiver-from-strict-compliance-with-rules-328-and-817-of-the-listing-rules-vii-change-of-authorized-representative-and-viii-continued-suspension-of-trading

The board (the "Board") of directors (the "Directors") of Ab&B Bio-Tech CO., LTD. JS (the "Company", together with its subsidiary, the "Group") hereby announces that, due to adjustment of work arrangements, Ms. LI Runxiang （李潤香**）("Ms. Li**") has tendered her resignation to the Board as, among others, an executive Director and the chief financial officer of the Company (the "Chief Financial Office

Ab&B Bio-Tech Co., Ltd. JS on 6ix

Earlier from Ab&B Bio-Tech Co., Ltd. JS

Later from Ab&B Bio-Tech Co., Ltd. JS

All Ab&B Bio-Tech Co., Ltd. JS news releases